PIA Executive Committee:



Chair: Andreas Monsch, PhD
Andreas Monsch received his PhD in 1991 from the University of Zuerich, Switzerland. He then completed a postdoctoral research fellowship with the late Professor Nelson Butters at UC San Diego until 1994. In 1994, Dr. Monsch returned to Switzerland and became director of research at the Memory Clinic of the University Hospital in Basel, Switzerland and was board-certified as a clinical neuropsychologist in 2001. In 2002, he became Head of the Memory Clinic. He joined the faculty of the University of Basel, Switzerland became an honorary professor in 2003.

Dr. Monsch has served and serves on several boards: International Neuropsychological Society (past governor), Swiss Memory Clinics (president 2008-2016), Swiss Association of Neuropsychology (current president), Alzheimer Forum Switzerland (current president). He has also served and serves on a number of Advisory Board of the pharmaceutical industry. Dr. Monsch's research interest focuses on the earliest detection of neurocognitive disorders and on rare causes of dementia. He has published more than 150 research articles and book chapters.    

Vice Chair: Douglas Galasko, MD
Dr. Douglas Galasko is a clinician-researcher whose research spans Alzheimer’s Disease, Parkinson’s Disease and other disorders resulting in cognitive impairment and dementia. He currently serves as Associate Director of the UCSD Shiley-Marcos Alzheimer's Disease Research Center (ADRC). He is a member of the Alzheimer’s Disease Cooperative Study, a NIH-funded consortium of medical Centers that conducts clinical trials in Alzheimer’s Disease.

In clinical practice, he provides expert evaluation and comprehensive care for patients with memory and cognitive disorders, including Alzheimer’s Disease, Frontotemporal Dementia, Progressive Aphasia, and Dementia with Lewy Bodies, at the UCSD Perlman Neurology Clinic. He also is a Staff Physician in the Neurology Service of the VA Medical Center, La Jolla, where he sees patients with a variety of neurological disorders.

Dr. Galasko has made research contributions in the area of Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and other disorders associated with cognitive impairment and dementia. He has helped to develop diagnostic criteria for AD, DLB and behavioral variant FTD, and has contributed to the International Working Group (IWG) criteria for terminology of Alzheimer;’s Disease in relation to biomarkers. He has authored over 300 journal articles, over 30 book chapters, and serves as Co-Editor of the journal Alzheimer’s Research and Therapy. Many of his publications are in areas such as cognitive characterization of MCI, DLB, and the relationship between cognition and function. He has served on committees to develop diagnostic criteria for Dementia with Lewy Bodies and to standardize biological sample collection for multicenter research studies.

He has received research funding from the National Institute on Aging, the State of California, the Alzheimer Association, the Michael J Fox Foundation and the Alzheimer’s Disease Drug Discovery Foundation. He also has conducted clinical trials with funding from Pfizer, Elan, Eli Lilly, Biogen and other companies.

He serves as a grant reviewer for the National Institutes of Health, the Veterans Administration, the Michael J Fox Foundation, the Bright Focus Foundation, and the American Federation for Aging Research. He serves on advisory boards for academic research groups and pharmaceutical companies.

Programs Chair: Mark Bondi, PhD
Mark Bondi received his PhD in clinical psychology and neuropsychology in 1991 from the University of Arizona.  He completed his internship and postdoctoral fellowship training at UC San Diego and joined the faculty in 1994.  He is currently Professor of Psychiatry at UC San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System.  He has served on several elected boards of the American Psychological Association, the Board of Directors of the American Board of Clinical Neuropsychology, and Board of Governors of the International Neuropsychological Society.  Since 1998 he has been board certified in Clinical Neuropsychology by the American Board of Professional Psychology.  Since 1991 he has received continuous funding from NIH, VA, Alzheimer's Association and private foundation grants, a Mid-Career Investigator Award in Patient-Oriented Research from NIA, and sponsored 18 NIH and VA career development awards of his current and former trainees.  His research centers on the cognitive and brain changes of individuals at risk for dementia, and he has published more than 195 articles, books, and book chapters.  He serves on the editorial boards of several journals, including the Journal of the International Neuropsychological Society, Neuropsychology, and as an Associate Editor of the Journal of Alzheimer's Disease.  He is a Fellow of the American Psychological Association and National Academy of Neuropsychology, and former President of the Society for Clinical Neuropsychology (Division 40 of APA).  

Communications Chair: David Salmon, PhD  
David Salmon is Professor-in-Residence and Helen A. Jarrett Chair in Alzheimer’s Disease Research in the Department of Neurosciences at the University of California, San Diego (UCSD), Co-Director of the UCSD Alzheimer's Disease Research Center (ADRC), and a member of the faculties of the Clinical Neuropsychology and Cognitive Sciences Programs at UCSD. His research focuses on the neuropsychology of memory and cognition, and on the cognitive deficits associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. His specific areas of interest include 1) the early detection of cognitive deficits and dementia in the elderly, 2) the identification of patterns of cognitive deficits that distinguish between cortical and subcortical dementia syndromes, and 3) the neuropsychological basis of episodic and semantic memory. Dr. Salmon has also conducted cross-cultural epidemiological research on the prevalence and neuropsychological features of dementia in China and on the island of Guam. Among the findings arising from his research are 1) the identification of patterns of cognitive deficits that can be used to diagnosis Alzheimer’s disease in its early stages, 2) evidence that the proximal cause of cognitive deficits in Alzheimer’s disease is the loss of synapses, and 3) the demonstration that disproportionately severe deficits in visual processing abilities differentiate patients with dementia with Lewy bodies from those with Alzheimer’s disease. Dr. Salmon received his Ph.D. in Biopsychology from Rutgers University (1984) and completed post-doctoral training in animal and human neuropsychology at UCSD (1984-1986). He has been affiliated with the UCSD ADRC since its inception in 1984 and a member of the UCSD faculty since 1987.  He served on the task force that developed the cognitive test battery that serves as the Uniform Data Set for the NIA-sponsored National Alzheimer Coordinating Center, and was a senior consultant that helped design the cognitive test battery used in the NIH- and Industry-sponsored Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Salmon has published over 350 journal articles and book chapters, and has served on the editorial boards of the Annual Review of Clinical Neuropsychology, The Journal of the International Neuropsychological Society, Neuropsychology, and The Journal of Clinical and Experimental Neuropsychology.